[CLSTR]
< Back to situations

[ORGANIZATION]

Istituto Pascale

Featured in 2 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [ES] [EU] [IT]

Ribociclib Natalee study breast cancer results

2 clusters · 8 sources · last updated

Latest: Ribociclib reduces early breast cancer death risk by 20% in 6-year study

Long-term data from the Phase III Natalee study indicates that ribociclib (Kisqali), when combined with hormone therapy, reduces the risk of death by approximately 19% to 20% in patients with early-stage, HR-positive, HE

Also covered in